Our results revealed an acquired vulnerability of resistant CCA cells to ribosome biogenesis stress, and drug synergism between CDK4/6 inhibitor and a drug already used in the treatment of CCA, oxaliplatin. This evidence concerns the gene CDK4 and cholangiocarcinoma.